0001193125-26-132085
SEC filingLexeo Therapeutics reported a net loss of $99.96 million for the year ended December 31, 2025, driven by continued investment in clinical development and operational expansion, with cash resources expected to support operations into 2028.
For the fiscal year ended December 31, 2025, Lexeo Therapeutics recorded an operating loss of $109.3 million, a 3.3% increase in deficit compared to $105.8 million in the prior year. This reflects the company’s ongoing commitment to advancing its gene therapy pipeline, particularly through later-stage clinical development, which inherently involves higher costs due to larger trial sizes and extended durations. The modest year-over-year change in operating performance indicates relative cost stability amid complex development activities.
Net loss for the period was $99.96 million, slightly wider than the $98.3 million loss in 2024, representing a 1.7% deterioration on an absolute basis. However, diluted EPS improved significantly to $-1.86 from $-3.09, a 39.8% improvement, driven by changes in share count or dilution assumptions rather than profitability gains. This divergence underscores that while economic losses persist, their distribution across shares has become less severe.
Cash used in operating activities rose to $98.56 million in 2025 from $81.15 million in 2024, highlighting increased near-term liquidity demands. This jump aligns with the company’s strategic focus on accelerating product candidate development and expanding operational capacity. Despite this, capital expenditures decreased to $397,000 from $481,000, indicating selective and efficient use of capital on infrastructure.
Free cash flow, calculated as operating cash flow minus capital expenditures, totaled $-99.0 million, closely tracking net loss. This reflects minimal non-cash offsetting benefits and confirms that clinical advancement remains heavily funded through external capital sources.
Since inception, Lexeo has generated no product revenue and continues to rely on its balance sheet—primarily U.S. Treasury securities and interest-bearing accounts—for liquidity. Management states these resources are sufficient to fund planned operations into 2028. However, it expects research, general administrative, and capital expenses to grow as lead programs advance. There is uncertainty around future collaborations, which could alter development timelines or funding needs. With no revenue horizon in sight, sustained net losses are anticipated for several years.